Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 20/20 | 0.63 |
| ▸ | BCL2 | P10415 | 2/20 | 0.59 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30000938 | 1.00 | MCL1 (0.63) | MCL1BCL2BCL2L1 | |
| SCHEMBL24745202 | 0.92 | MCL1 (0.68) | MCL1BCL2BCL2L1 | |
| SCHEMBL30000955 | 0.92 | MCL1 (0.68) | MCL1BCL2BCL2L1 | |
| SCHEMBL30000751 | 0.92 | MCL1 (0.61) | MCL1BCL2BCL2L1 | |
| SCHEMBL24745169 | 0.92 | MCL1 (0.61) | MCL1BCL2BCL2L1 | |
| SCHEMBL24744707 | 0.87 | MCL1 (0.69) | MCL1BCL2BCL2L1 | |
| SCHEMBL30000916 | 0.86 | MCL1 (0.67) | MCL1BCL2BCL2L1 | |
| SCHEMBL24745257 | 0.86 | MCL1 (0.67) | MCL1BCL2BCL2L1 | |
| SCHEMBL24745244 | 0.84 | MCL1 (0.57) | MCL1 | |
| SCHEMBL24772877 | 0.82 | MCL1 (0.58) | MCL1BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |